Genzyme Articles
Genzyme Appointment
20 February 1995
Celtrix Pulls BetaKine Out Of Ophthalmics
13 February 1995
NEW YORK STOCK COMMENT
6 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
US Health Care Still Bullish But Shakeout For Biotech
23 January 1995
Genzyme Appointment
23 January 1995
US Biotech Patent Rules Eased
9 January 1995
Oligopoly The Future For The Pharma Industry
2 January 1995
Genzyme BioSurface Deal Approved
19 December 1994
Phase II/III Study Of TretinoinLF In KS
19 December 1994
NEW YORK STOCK COMMENT
12 December 1994
RAC Approves Gene Therapies For Cancer, CF
12 December 1994
World Immunology, Rheumatology Markets
28 November 1994
Genzyme's Thyrogen Available In USA
21 November 1994
Genzyme Promotion
21 November 1994
Mixed Quarterly Results From The USA
14 November 1994
Lower Earnings For Some US Drugmakers In 3rd Qtr
7 November 1994
Genzyme/IntroGene Agreement
10 October 1994
Hoechst Pharma's International Outlook
10 October 1994
Genzyme's Thyrogen
3 October 1994
Ceredase Approval in Europe
5 September 1994
Mixed Results From US Companies In 2nd Qtr
8 August 1994
Genzyme Makes Biosurface M&A
1 August 1994
Genzyme Forms Wound Healing Specialist Arm
1 August 1994
NEW YORK STOCK COMMENT
25 July 1994
Swiss Firm Sygena Bought By Genzyme
25 July 1994
GENZYME ACQUISITION
18 July 1994
CELTRIX AND GENZYME LINK UP OVER BETAKINE
4 July 1994
US HOUSE PANEL OKS BIOTECH AMENDMENT
27 June 1994
BIOPHARMA GROWTH MARKETS OF THE FUTURE
27 June 1994
NEW YORK STOCK COMMENT
20 June 1994
CEREZYME APPROVED IN USA
6 June 1994
BIOTECH FIRMS PRAISED OVER COSTS
6 June 1994
1ST QUARTER RESULTS VARY FOR US FIRMS
23 May 1994
BIOTECH COMPANIES REPORT ON PROGRESS
16 May 1994
GENZYME TRANSGENICS
9 May 1994
$7.7 MILL GENZYME TRANSGENICS JV
2 May 1994
DINGELL "WILL KILL DRUG REVIEW COUNCIL PLAN"
2 May 1994
THE ULTIMATE FORM OF MOLECULAR MEDICINE?
2 May 1994
KIDDER, PEABODY ON BIOTECHNOLOGY
2 May 1994
NEW YORK STOCK COMMENT
11 April 1994
CEREDASE APPROVED IN EU
11 April 1994
NEOZYME II FIRST FULL-YEAR RESULTS
4 April 1994
REVENUES COME IN FROM BETASERON AT CHIRON
14 March 1994
GENZYME APPOINTMENT
31 January 1994
CHRONIMED GAINS L-CYCLOSERINE LICENSE
24 January 1994
GENZYME APPOINTMENT
17 January 1994
GENZYME TRANSGENICS REPORTS SUCCESS
17 January 1994
1992 SEES SMALLER COMPANY MERGERS
10 January 1994
GENZYME ACQUISITION
13 December 1993
R-P HALTS ALBUMIN PRODUCTION
6 December 1993
NEW YORK STOCK COMMENT
6 December 1993
US 3rd QUARTER RESULTS - SOME IMPROVEMENT
6 December 1993
US BIOTECH AND SMALL DRUG COs STEADY
22 November 1993
CURRENCY EXCHANGE FACTOR HITS US 3rd QTR
8 November 1993
XENOVA AND FMC CORP IN LINK-UP
11 October 1993
NEW YORK STOCK COMMENT
11 October 1993
GENZYME APPOINTMENT
27 September 1993
GENZYME GAINS US PATENT
27 September 1993
GENZYME TO MARKET ARGUS' TRETINOIN LF
20 September 1993
US INDUSTRY ASSESSES RX MEDICARE COVER PLAN
20 September 1993
SMALLER US COMPANIES POST MIXED RESULTS
16 August 1993
US QUARTERLY RESULTS REVEAL GROWTH
9 August 1993
GENZYME OPENS MARKET
26 July 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
NICHE MARKETING IN THE BIOTECH INDUSTRY
26 July 1993
GENZYME RESIGNATION
5 July 1993
NEW YORK STOCK COMMENT
5 July 1993
OPPORTUNITIES IN UK BIOSCIENCE SECTOR
21 June 1993
GENZYME FILES NDA
7 June 1993
GENZYME SHARE ISSUE
31 May 1993
GENZYME CORP COLLABORATION
31 May 1993
GENZYME ACQUISITIONS
24 May 1993
DRUG PLAN WILL HARM BIO-INDUSTRY
17 May 1993
GENZYME TRIALS OF RECOMBINANT CEREDASE
10 May 1993
STRONG GROWTH BY US PHARMA COs IN 1st QTR
10 May 1993
US NIH INABILITY TO ENFORCE FAIR PRICING
3 May 1993
XENOVA'S PRIVATE PLACEMENT A SUCCESS
15 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
US BIOTECHNOLOGY COS REPORT 1992 RESULTS
15 March 1993
XENOVA IN CLINIC WITHIN 12 TO 18 MONTHS?
8 March 1993
SANDOZ DEAL WITH SCRIPPS QUESTIONED
22 February 1993
GENZYME GOES FOR NICHES
8 February 1993
DRUG COST/EFFICACY ADDED CRITERION IN USA?
1 February 1993
GENZYME APPOINTMENT
25 January 1993
GENZYME GENE THERAPY APPROVAL
4 January 1993
1992 SEES SMALLER COMPANY MERGERS
4 January 1993
GENZYME GAINS PATENTS
21 December 1992
TRANSFORMATION OF ENZYMATIX
21 December 1992
CHEAPER TREATMENT WITH CEREDASE?
14 December 1992
US DRUG ANALYSTS VIEW CLINTON WIN
9 November 1992
CLINTON: NO SHORT TERM CHANGES EXPECTED
9 November 1992
CEREDASE PRICING CRITICIZED BY OTA
12 October 1992
GENZYME BUYS BACK NEOZYME PROGRAMS
3 August 1992
Integrated Genetics acquires Genetech
29 June 1992
US COMPANY NEWS IN BRIEF
15 June 1992
stock commentary: New York
1 June 1992
VIANAIN US PATENT
18 May 1992
SMALLER US COMPANIES POST GOOD RESULTS
18 May 1992
XENOVA - HENRI TERMEER
11 May 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
